<DOC>
	<DOCNO>NCT02178748</DOCNO>
	<brief_summary>Mycobacterium tuberculosis ( M. tb ) pathogen worldwide distribution infects human cause tuberculosis ( TB ) , transmissible disease result high mortality morbidity ; development effective vaccine global health priority . Over billion people worldwide infect one helminth . Helminths parasitic worm , Schistosoma mansoni one specie . There evidence helminth infection may affect person 's response vaccine . In trial investigator hope investigate whether Schistosoma mansoni infection affect adolescent ' response candidate TB vaccine call MVA85A , adolescents crucial target group effective TB vaccine .</brief_summary>
	<brief_title>Trial Investigate Effect Schistosoma Mansoni Infection Response Vaccination With MVA85A BCG-vaccinated African Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Participants must meet follow criterion enter trial : Healthy adolescent age 1217 year ( male female ) Resident study area duration study period Confirmation prior vaccination BCG le 6 month prior project study vaccination date ( visible BCG scar examination write documentation ) No relevant finding medical history physical examination Written inform consent parent guardian Written inform assent subject Refrain blood donation trial Agree avoid pregnancy duration trial ( female ) Able willing ( Investigator 's opinion ) comply study requirement Stool sample negative S. mansoni ( group 1 ) positive S. mansoni infection ( group 2 ) , base result Kato Katz stool analysis Willing delay treatment schistosomiasis least one month ( group 2 ) Exclusion Criteria Participants may enter trial ANY follow apply : Clinical , radiological , laboratory evidence current active TB disease Laboratory evidence screen latent M. tb infection indicate positive ELISPOT response ESAT6 CFP10 antigens Previous treatment active latent tuberculosis infection Shared residence within one year prior day 0 individual antituberculosis treatment culture smearpositive pulmonary tuberculosis Received TST within 90 day prior day 0 Clinically significant history skin disorder , allergy , immunodeficiency ( include HIV ) , cancer ( except BCC CIS ) , cardiovascular disease , gastrointestinal disease , liver disease , renal disease , endocrine disorder neurological illness , drug alcohol abuse History serious psychiatric condition disorder Concurrent oral systemic steroid medication concurrent use immunosuppressive agent within 2 month prior enrolment History anaphylaxis vaccination allergy likely exacerbate component study vaccine , include egg Any abnormality screen blood urine test deem clinically significant may compromise safety volunteer study Positive HBsAg , HCV HIV antibody Use investigational medicinal product nonregistered drug , live vaccine , medical device study vaccine 30 day prior dose study vaccine , plan use study period Administration immunoglobulins and/or blood product within three month precede plan trial vaccination date Female currently lactate , confirmed pregnancy intention become pregnant trial period Screening blood sample positive malaria Mansonella perstans microscopy Schistosoma mansoni infection intensity great 2000 egg per gram stool Any three screen stool sample positive helminth Kato Katz examination S. mansoni Strongyloides stercoralis PCR ( group 1 ) ; three screen stool sample positive helminth S. mansoni Kato Katz examination Strongyloides stercoralis PCR ( group 2 ) Screening urine sample positive S. mansoni infection ( group 1 ) Any significant disease , disorder , finding , , opinion Investigator , may either put subject risk may influence result trial may affect subject 's ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Phase II</keyword>
	<keyword>MVA85A</keyword>
	<keyword>Schistosoma mansoni</keyword>
</DOC>